Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Adding carboplatin to mirvetuximab produces response levels comparable to single-agent antibody-drug conjugate data rather than marked synergy. Using single-agent ADC therapy in platinum-sensitive recurrence following PARP inhibitor progression provides effective disease control while conserving platinums for later lines.

Related Insights

The treatment landscape for platinum-resistant ovarian cancer has rapidly evolved into a biomarker-driven paradigm. Clinicians must now test for and choose between therapies targeting distinct markers like folate receptor alpha (mirvetuximab), HER2 (T-DXd), and PD-L1 (pembrolizumab), requiring a sophisticated sequencing strategy.

The traditional six-month timeframe for defining platinum sensitivity is being challenged. A growing theory suggests that tumors progressing while on a PARP inhibitor have a distinct biology that responds poorly to subsequent platinum, indicating a potential need to move directly to therapies like ADCs.

Real-world data shows that in platinum-sensitive ovarian cancer patients who have progressed on PARP inhibitors, subsequent platinum-based chemotherapy has a surprisingly low response rate of only 20%. This quantifies a significant opportunity for highly active ADCs to potentially replace platinum in this growing patient population.

The widespread use of PARP inhibitors has altered tumor biology in platinum-sensitive ovarian cancer. A recent meta-analysis of heavily pretreated patients, 97% of whom had prior PARP inhibitor exposure, revealed an objective response rate to subsequent therapy of only 17%—far lower than historical expectations, highlighting a critical unmet clinical need.

Patients whose ovarian cancer progresses on the folate-targeted ADC mirvetuximab may still respond to a subsequent folate-targeted ADC with a different cytotoxic payload. This suggests that the folate receptor alpha target remains viable and that resistance may be payload-specific, opening new sequencing strategies.

Early clinical trial data for the ADC mirvetuximab shows a response rate of 39% in patients with one to three prior lines of therapy. This rate drops significantly for patients with four or more lines, supporting prioritization of this drug earlier in the platinum-resistant setting.

For HRD-positive ovarian cancer, a strong initial response to platinum chemotherapy may justify using a PARP inhibitor alone for maintenance. A weaker response, however, suggests adding bevacizumab for a potentially greater benefit, using clinical response as a key decision-making tool.

Next-generation topoisomerase I payload ADCs are showing up to 50% response rates in platinum-resistant ovarian cancer without requiring high biomarker expression. Unlike mirvetuximab or trastuzumab deruxtecan, these emerging agents could broaden clinical accessibility to broader patient populations without upfront IHC biomarker stratification.

When selecting initial ADC therapy for ovarian cancer patients with dual biomarker expression (FR-alpha positive and HER2-positive), clinicians favor starting with mirvetuximab soravtansine over trastuzumab deruxtecan. Initiating mirvetuximab captures its proven overall survival advantage while keeping trastuzumab deruxtecan available as an effective option for subsequent sequencing.

A key challenge is treating ovarian cancer that progresses on PARP inhibitors. A subgroup analysis of the REJOYCE study found that the cadherin-6-directed ADC, Ralodotatug deruxtecan (RDXD), had a high response rate of 58% in this specific, difficult-to-treat population, positioning it as a potential future therapy for this clinical scenario.

Omit Platinums in Post-PARP Sensitive Ovarian Cancer When Using Folate Receptor ADCs | RiffOn